{
    "clinical_study": {
        "@rank": "15075", 
        "arm_group": {
            "arm_group_label": "Oxaloacetate (OAA)", 
            "arm_group_type": "Experimental", 
            "description": "100 mg OAA to be taken twice daily over the course of a month"
        }, 
        "brief_summary": {
            "textblock": "By doing this study, researchers hope to learn how much oxaloacetate (OAA) ends up in the\n      blood after OAA capsules are swallowed, and to assess whether persons with Alzheimer's\n      disease who take OAA for one month have any side-effects."
        }, 
        "brief_title": "Oxaloacetate Pharmacokinetics and Safety", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meet criteria for Mild or Moderate AD\n\n          -  Have a study partner\n\n          -  Speak English as primary language.\n\n        Exclusion Criteria:\n\n          -  Absence of a study partner\n\n          -  Report a potentially confounding, serious medical risk such as type 1 diabetes,\n             cancer, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063308", 
            "org_study_id": "STUDY00000581"
        }, 
        "intervention": {
            "arm_group_label": "Oxaloacetate (OAA)", 
            "intervention_name": "Oxaloacetate (OAA)", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Oxaloacetate", 
            "OAA", 
            "AD", 
            "Alzheimer's Disease"
        ], 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66160"
                }, 
                "name": "University of Kansas Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Oxaloacetate Pharmacokinetics and Safety", 
        "overall_contact": {
            "email": "rbothwell@kumc.edu", 
            "last_name": "Rebecca Bothwell, MS", 
            "phone": "(913) 945-5033"
        }, 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Russell Swerdlow, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Baseline blood sample will be obtained before 100 mg OAA is administered. Blood samples to be drawn every 15 minutes starting 30 minutes after OAA administration.", 
            "measure": "Correlation between oral OAA intake and plasma levels", 
            "safety_issue": "No", 
            "time_frame": "Change from dose to 30, 45, 60, 75, 90, 105, 120, 135, 150, and 240 minutes after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063308"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kansas Medical Center Research Institute", 
            "investigator_full_name": "Russell Swerdlow, MD", 
            "investigator_title": "Gene and Marge Sweeney Professor of Neurology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "We will evaluate weights, blood counts, electrolytes, liver function tests, insulin levels, and plasma amino acid levels in subjects exposed to OAA for 1 month. These multiple measures will be used to generate a composite safety outcome measure.", 
            "measure": "safety of OAA in study participants", 
            "safety_issue": "Yes", 
            "time_frame": "Change from Baseline to Month 1"
        }, 
        "source": "University of Kansas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Russell Swerdlow, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}